These studies have limitations, including lack of standard randomization by biomarker status, leading to more favorable tumor subtypes in the surgically treated group in the trial demonstrating survival benefit with surgery,44 while the trial led by Badwe et al47 did not utilize HER2-targeted therapy in patients with HER2-positive disease. Here, ERBB2 is linked to neoplasm.